Natco Pharma ventures into Pheromone based technology for Integrated Pest Management

Published On 2021-03-16 06:45 GMT   |   Update On 2021-03-16 10:27 GMT

Hyderabad: Natco Pharma Limited has recently announced that the company ventured into Pheromone based mating disruption technology for Integrated Pest Management (IPM) solution to farmers in India. NATCO through its Crop Health Science (CHS) division is working with ATGC Biotech Pvt Ltd (ATGC) for the technology. ATGC is a science based innovative technology company concentrating...

Login or Register to read the full article

Hyderabad: Natco Pharma Limited has recently announced that the company ventured into Pheromone based mating disruption technology for Integrated Pest Management (IPM) solution to farmers in India.

NATCO through its Crop Health Science (CHS) division is working with ATGC Biotech Pvt Ltd (ATGC) for the technology.

ATGC is a science based innovative technology company concentrating on developing new biosafe molecules and tools to protect diverse crops from insect pests, in collaboration with US based agricultural biotech company ISCA Inc.

During Kharif 2021, NATCO plans to launch its first Green Label Pheromone product for Effective Management of Pink Bollworm (PBW) in cotton crop, under its brand NATMATE PBW. This is the first pheromone-based indigenously manufactured product for mating disruption that received approval from Central Insecticide Board (CIB). With this launch, cotton farmers will have a new and powerful tool to manage PBW.

Read also: Natco pharma launches epilepsy drug Brivaracetam in India

Pink Bollworm posed a major challenge in the past few years to cotton farmers across India. The damage to quality and yield of cotton due to PBW is significant and often severely affects the livelihood of small farmers. Now, NATMATE PBW will be a tool in the hands of farmers and seed producers in developing an Insect Resistance Management (IRM) plan and preserve benefits of Bt traits in cotton as well.

Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.

The Company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc.


Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News